ID   CAL-27 TPFR
AC   CVCL_GY99
DR   Wikidata; Q54808395
RX   PubMed=25962396;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere).
CC   Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
DI   NCIt; C173807; Tongue adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1107 ! CAL-27
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 29-06-23; Version: 14
//
RX   PubMed=25962396; DOI=10.3892/mmr.2015.3768;
RA   Govindan S.V., Kulsum S., Pandian R.S., Das D., Seshadri M.,
RA   Hicks W. Jr., Kuriakose M.A., Suresh A.;
RT   "Establishment and characterization of triple drug resistant head and
RT   neck squamous cell carcinoma cell lines.";
RL   Mol. Med. Rep. 12:3025-3032(2015).
//